title: A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas.
abstract: BACKGROUND
  Surgical biopsy examination is the gold standard for lymphoma diagnostics. However, fine-needle aspiration cytology (FNAC) offers several advantages in that it is quick, inexpensive, and the aspiration procedure has very few complications. This prospective study compares the diagnostic outcome between FNAC and surgical biopsy.
  
  
  METHODS
  A total of 103 patients (>15 years) with lymphadenopathy and accessible lymph nodes underwent both diagnostic procedures. Immunophenotyping was performed on both FNAC and histopathological specimens. The updated KIEL classification was used for primary diagnosis and the WHO classification for reclassification.
  
  
  RESULTS
  FNAC- and histopathology-based diagnoses were concordant in 76 patients. In 10 patients, there was a major diagnostic discordance: four differed with regard to degree of malignancy (low- versus high-grade NHL), three lymphoma versus reactive changes, and three regarding Hodgkin's lymphoma versus anaplastic large cell lymphoma. In 10 patients there was some (minor) discordance regarding subclassification: in eight patients the results of immunophenotyping differed, in two cases there were discrepancies in the cell type classification. In the remaining seven cases, there were diagnostic difficulties due to an insufficient sample. two serious adverse events occurred following surgical biopsy.
  
  
  CONCLUSIONS
  FNAC is an accurate method in the diagnosis of lymphomas when the cytologic diagnosis is corroborated by immunophenotyping. However, an increasing use of FNAC for primary diagnosis and classification of lymphomas may result in a loss of archival tissue for complementary analyses, reclassification, and research purposes. In addition, some of the lymphoma entities are impossible to diagnose with use of the FNAC technique.
authors.affiliation: Department of Hematology, Karolinska Hospital and Institutet, Stockholm, Sweden. ola.landgren@ks.se
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
authors.forename: Anna
authors.initials: A
authors.lastname: Porwit MacDonald
authors.forename: Edneia
authors.initials: E
authors.lastname: Tani
authors.forename: Magdalena
authors.initials: M
authors.lastname: Czader
authors.forename: Gunnar
authors.initials: G
authors.lastname: Grimfors
authors.forename: Lambert
authors.initials: L
authors.lastname: Skoog
authors.forename: Ake
authors.initials: A
authors.lastname: Ost
authors.forename: Christina
authors.initials: C
authors.lastname: Wedelin
authors.forename: Ulla
authors.initials: U
authors.lastname: Axdorph
authors.forename: Erik
authors.initials: E
authors.lastname: Svedmyr
authors.forename: Magnus
authors.initials: M
authors.lastname: Björkholm
mesh_terms: D000368:Aged; D001706:Biopsy / Q000009:adverse effects / Q000592:standards*; D044963:Biopsy, Fine-Needle / Q000009:adverse effects / Q000592:standards*; D003951:Diagnostic Errors; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D008223:Lymphoma / Q000145:classification* / Q000175:diagnosis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies